Qual Holdings --- Monthly Report (Consolidated) Achievements for November 2024.

QOL Holdings <3034> announced its monthly report (consolidated) for November 2024 on the 13th. The number of prescription requests for the month of November was 104.9% compared to the same month last year, and the dispensing fees were 104.0%. In November, both prescription requests and dispensing fees increased due to contributions from M&A and new store openings. The status of the group's stores is as follows. Regarding new openings, in November, QOL Anywhere Pharmacy (Saitama Prefecture) opened, and in December, QOL Pharmacy Nitori Mo was planned.

Fisco JapanDec 17 08:54

Quorl HD - New release of 3 ingredients and 7 items of authorized generic pharmaceuticals.

On the 5th, Quall Holdings <3034> announced that its subsidiary Daiichi Sankyo Esfa will launch three components and seven types of authorized generic (AG) pharmaceuticals that were announced in the official gazette on the 6th. Daiichi Sankyo Esfa provides high value-added generic pharmaceuticals, as well as raw materials, additives, and manufacturing methods that are the same as those of new drugs (original pharmaceuticals). The newly launched product is rivaroxaban tablets, a selective direct factor Xa inhibitor.

Fisco JapanDec 6 14:25

Qual Holdings---Newly launched 7 items of authorized generic pharmaceuticals with 3 components.

On the 5th, Quore Holdings <3034> announced that its subsidiary Daiichi Sankyo Esfa will launch three new authorized generic (AG) pharmaceutical products with seven varieties, as published in the official gazette, on the 6th. Daiichi Sankyo Esfa offers high-value-added generic pharmaceuticals that feature innovations in formulation, labeling, and packaging, as well as AGs that are identical to new drugs (originator pharmaceuticals) in terms of active ingredients, additives, and manufacturing processes. The newly released product is Rivaroxaban tablets, a selective direct factor Xa inhibitor.

Fisco JapanDec 6 14:24

Qol Holdings: Confirmation letter

EDINETNov 14 08:20 · Announcements

Qol Holdings: Semi-annual report - 33rd period (2024/04/01 - 2025/03/31)

EDINETNov 14 08:19 · Announcements

Qual HD - 2Q revenue, operating profit, and ordinary profit all increased by double digits, with significant expansion of the pharmaceutical business scale.

Quol Holdings <3034> announced its consolidated financial results for the second quarter of the fiscal year ending March 2025 (April-September 24). Revenue increased by 40.9% year-on-year to 124.771 billion yen, operating profit increased by 71.3% to 6.096 billion yen, ordinary profit increased by 69.2% to 6.22 billion yen, and interim net profit attributable to parent company shareholders decreased by 35.8% to 1.211 billion yen. The revenue of the pharmacy business increased by 3.8% year-on-year to 84.08 billion yen, and operating profit decreased by 10.2%.

Fisco JapanNov 7 09:17